HOOKIPA Pharma’s $84 Million Initial Public Offering

Goodwin advised HOOKIPA Pharma on the transaction, Shearman & Sterling advised the underwriters.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share. In addition, HOOKIPA has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $84 million, excluding any exercise of the underwriters’ option to purchase additional shares.

HOOKIPA plans to use the offering proceeds to advance HB-101, its lead product candidate in infectious diseases for the prevention of cytomegalovirus infections, through completion of the ongoing Phase 2 clinical trial, to advance HB-201 and HB-202, its lead oncology product candidates for cancers caused by human papilloma virus into and through completion of Phase 1 clinical trials, as well as to advance HB-301, its product candidate in metastatic, hormone-resistant prostate cancer into and through a Phase 1 clinical trial. Furthermore, HOOKIPA intends to further progress its earlier pipeline projects and ongoing research and development activities as well as for working capital and other general corporate purposes.

BofA Merrill Lynch, SVB Leerink, and RBC Capital Markets are serving as joint book-running managers for the offering. Kempen is acting as a co-manager for the offering.

The Goodwin team was led by partners Seo Salimi (Picture), Robert Puopolo and Kingsley Taft, and associates Michelle Wilensky, Will Magioncalda, Nicholas Reist and Thomas Schaad with assistance from partners Duncan Greenhalgh, Roger Cohen, Ettore Santucci and Rick Kline, counsel Stephanie Philbin, associates Olivia Uitto, Elizabeth Mulkey, Allyson Maur and paralegals Pamela Finan and Nathan Needle.

Shearman & Sterling advised the underwriters with a team including Ilir Mujalovic, Maria Marulanda Larsen, Natalie Ko, Yeonsue Kim, Richard Alsop, Harald Halbhuber, Doreen E. Lilienfeld, Jordan Altman, Jennifer D. Morton, Y. Jingjing Liang, Adam Sternberg, JB Betker, Puja Dave, Jenny Ding Jordan and P. Sean Kelly

Involved fees earner: Roger Cohen – Goodwin Procter; Duncan Greenhalgh – Goodwin Procter; Richard Kline – Goodwin Procter; William Magioncalda – Goodwin Procter; Allyson Maur – Goodwin Procter; Elizabeth Mulkey – Goodwin Procter; Stephanie Philbin – Goodwin Procter; Robert Puopolo – Goodwin Procter; Nicholas Reist – Goodwin Procter; Seo Salimi – Goodwin Procter; Ettore Santucci – Goodwin Procter; Kingsley Taft – Goodwin Procter; Olivia Uitto – Goodwin Procter; Michelle Wilensky – Goodwin Procter; Richard Alsop – Shearman & Sterling; Jordan Altman – Shearman & Sterling; JB Betker – Shearman & Sterling; Puja Dave – Shearman & Sterling; Jenny Ding Jordan – Shearman & Sterling; Harald Halbhuber – Shearman & Sterling; Sean Kelly – Shearman & Sterling; Yeonsue Kim – Shearman & Sterling; Natalie Ko – Shearman & Sterling; Jingjing Liang – Shearman & Sterling; Doreen Lilienfeld – Shearman & Sterling; Maria Marulanda Larsen – Shearman & Sterling; Jennifer D. Morton – Shearman & Sterling; Ilir Mujalovic – Shearman & Sterling; Adam Sternberg – Shearman & Sterling;

Law Firms: Goodwin Procter; Shearman & Sterling;

Clients: Bank of America Merrill Lynch; Hookipa Pharma Inc. ; RBC Capital Markets; SVB Leerink LLC;

Author: Ambrogio Visconti